Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer

Naofumi Kagara, Kelly T. Huynh, Christine Kuo, Hideyuki Okano, Myung Shin Sim, David Elashoff, Kelly Chong, Armando E. Giuliano, Dave S B Hoon

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Expression of specific breast cancer stem cells (BCSCs) is seen in aggressive tumors, but their regulation is unclear. Epigenetic changes influence gene expression and are implicated in breast cancer progression. We hypothesized that promoter methylation regulates specific BCSC-related genes [CD44, CD133, CD24, MSH1 (alias, Musashi-1), and ALDH1] and that this epigenetic profile can identify aggressive subtypes, such as triple-negative breast cancer (TNBC). Methylation analysis was performed using MassARRAY EpiTYPER sequencing; CpG-rich sites were identified in the promoter regions of BCSC genes, except ALDH1. These sites were screened by treatment with 5-aza-2′-deoxycytidine in four TN and five non-TNBC cell lines. The specific regulatory CpG site demonstrating the most significant inverse correlation between CpG site methylation and mRNA expression was identified for CD44, CD133, and Musashi-1, but not for CD24. Methylation of CD44, CD133, and Musashi-1 was evaluated in 91 American Joint Committee on Cancer stage I to III primary breast cancer tumors, and these sites were significantly hypomethylated in TNBC versus non-TNBC. The IHC staining of primary tumors with the highest and lowest methylation levels revealed the strongest staining in hypomethylated specimens, suggesting that hypomethylation leads to gene activation. We demonstrate that methylation is a significant mechanism regulating CD44, CD133, and Musashi-1, and that gene hypomethylation correlates with TNBC. Assessment of epigenetic changes in BCSC genes may provide a more accurate classification of TNBC and could be developed as potential therapeutic targets.

Original languageEnglish
Pages (from-to)257-267
Number of pages11
JournalAmerican Journal of Pathology
Volume181
Issue number1
DOIs
Publication statusPublished - 2012 Jul

Fingerprint

Triple Negative Breast Neoplasms
Neoplastic Stem Cells
Epigenomics
Breast Neoplasms
Methylation
Genes
decitabine
Staining and Labeling
Neoplasms
Genetic Promoter Regions
Transcriptional Activation
Gene Expression
Cell Line

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. / Kagara, Naofumi; Huynh, Kelly T.; Kuo, Christine; Okano, Hideyuki; Sim, Myung Shin; Elashoff, David; Chong, Kelly; Giuliano, Armando E.; Hoon, Dave S B.

In: American Journal of Pathology, Vol. 181, No. 1, 07.2012, p. 257-267.

Research output: Contribution to journalArticle

Kagara, N, Huynh, KT, Kuo, C, Okano, H, Sim, MS, Elashoff, D, Chong, K, Giuliano, AE & Hoon, DSB 2012, 'Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer', American Journal of Pathology, vol. 181, no. 1, pp. 257-267. https://doi.org/10.1016/j.ajpath.2012.03.019
Kagara, Naofumi ; Huynh, Kelly T. ; Kuo, Christine ; Okano, Hideyuki ; Sim, Myung Shin ; Elashoff, David ; Chong, Kelly ; Giuliano, Armando E. ; Hoon, Dave S B. / Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. In: American Journal of Pathology. 2012 ; Vol. 181, No. 1. pp. 257-267.
@article{3c16b3f3465e42d8928be3ebffad6c03,
title = "Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer",
abstract = "Expression of specific breast cancer stem cells (BCSCs) is seen in aggressive tumors, but their regulation is unclear. Epigenetic changes influence gene expression and are implicated in breast cancer progression. We hypothesized that promoter methylation regulates specific BCSC-related genes [CD44, CD133, CD24, MSH1 (alias, Musashi-1), and ALDH1] and that this epigenetic profile can identify aggressive subtypes, such as triple-negative breast cancer (TNBC). Methylation analysis was performed using MassARRAY EpiTYPER sequencing; CpG-rich sites were identified in the promoter regions of BCSC genes, except ALDH1. These sites were screened by treatment with 5-aza-2′-deoxycytidine in four TN and five non-TNBC cell lines. The specific regulatory CpG site demonstrating the most significant inverse correlation between CpG site methylation and mRNA expression was identified for CD44, CD133, and Musashi-1, but not for CD24. Methylation of CD44, CD133, and Musashi-1 was evaluated in 91 American Joint Committee on Cancer stage I to III primary breast cancer tumors, and these sites were significantly hypomethylated in TNBC versus non-TNBC. The IHC staining of primary tumors with the highest and lowest methylation levels revealed the strongest staining in hypomethylated specimens, suggesting that hypomethylation leads to gene activation. We demonstrate that methylation is a significant mechanism regulating CD44, CD133, and Musashi-1, and that gene hypomethylation correlates with TNBC. Assessment of epigenetic changes in BCSC genes may provide a more accurate classification of TNBC and could be developed as potential therapeutic targets.",
author = "Naofumi Kagara and Huynh, {Kelly T.} and Christine Kuo and Hideyuki Okano and Sim, {Myung Shin} and David Elashoff and Kelly Chong and Giuliano, {Armando E.} and Hoon, {Dave S B}",
year = "2012",
month = "7",
doi = "10.1016/j.ajpath.2012.03.019",
language = "English",
volume = "181",
pages = "257--267",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer

AU - Kagara, Naofumi

AU - Huynh, Kelly T.

AU - Kuo, Christine

AU - Okano, Hideyuki

AU - Sim, Myung Shin

AU - Elashoff, David

AU - Chong, Kelly

AU - Giuliano, Armando E.

AU - Hoon, Dave S B

PY - 2012/7

Y1 - 2012/7

N2 - Expression of specific breast cancer stem cells (BCSCs) is seen in aggressive tumors, but their regulation is unclear. Epigenetic changes influence gene expression and are implicated in breast cancer progression. We hypothesized that promoter methylation regulates specific BCSC-related genes [CD44, CD133, CD24, MSH1 (alias, Musashi-1), and ALDH1] and that this epigenetic profile can identify aggressive subtypes, such as triple-negative breast cancer (TNBC). Methylation analysis was performed using MassARRAY EpiTYPER sequencing; CpG-rich sites were identified in the promoter regions of BCSC genes, except ALDH1. These sites were screened by treatment with 5-aza-2′-deoxycytidine in four TN and five non-TNBC cell lines. The specific regulatory CpG site demonstrating the most significant inverse correlation between CpG site methylation and mRNA expression was identified for CD44, CD133, and Musashi-1, but not for CD24. Methylation of CD44, CD133, and Musashi-1 was evaluated in 91 American Joint Committee on Cancer stage I to III primary breast cancer tumors, and these sites were significantly hypomethylated in TNBC versus non-TNBC. The IHC staining of primary tumors with the highest and lowest methylation levels revealed the strongest staining in hypomethylated specimens, suggesting that hypomethylation leads to gene activation. We demonstrate that methylation is a significant mechanism regulating CD44, CD133, and Musashi-1, and that gene hypomethylation correlates with TNBC. Assessment of epigenetic changes in BCSC genes may provide a more accurate classification of TNBC and could be developed as potential therapeutic targets.

AB - Expression of specific breast cancer stem cells (BCSCs) is seen in aggressive tumors, but their regulation is unclear. Epigenetic changes influence gene expression and are implicated in breast cancer progression. We hypothesized that promoter methylation regulates specific BCSC-related genes [CD44, CD133, CD24, MSH1 (alias, Musashi-1), and ALDH1] and that this epigenetic profile can identify aggressive subtypes, such as triple-negative breast cancer (TNBC). Methylation analysis was performed using MassARRAY EpiTYPER sequencing; CpG-rich sites were identified in the promoter regions of BCSC genes, except ALDH1. These sites were screened by treatment with 5-aza-2′-deoxycytidine in four TN and five non-TNBC cell lines. The specific regulatory CpG site demonstrating the most significant inverse correlation between CpG site methylation and mRNA expression was identified for CD44, CD133, and Musashi-1, but not for CD24. Methylation of CD44, CD133, and Musashi-1 was evaluated in 91 American Joint Committee on Cancer stage I to III primary breast cancer tumors, and these sites were significantly hypomethylated in TNBC versus non-TNBC. The IHC staining of primary tumors with the highest and lowest methylation levels revealed the strongest staining in hypomethylated specimens, suggesting that hypomethylation leads to gene activation. We demonstrate that methylation is a significant mechanism regulating CD44, CD133, and Musashi-1, and that gene hypomethylation correlates with TNBC. Assessment of epigenetic changes in BCSC genes may provide a more accurate classification of TNBC and could be developed as potential therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=84862640558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862640558&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2012.03.019

DO - 10.1016/j.ajpath.2012.03.019

M3 - Article

C2 - 22626806

AN - SCOPUS:84862640558

VL - 181

SP - 257

EP - 267

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 1

ER -